Shifting to sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience

Po-Ting Lin; Rachel Wen-Juei Jeng; Yi-Chung Hsieh; Wei Teng; Chen-Fu Hung; Chien-Hao Huang; Kar-Wai Lui; Yi-Cheng Chen; Chen-Chun Lin; Chun-Yen Lin; Shi-Ming Lin; I-Shyan Sheen

doi:10.1016/S0618-8278(19)31232-0

Shifting to sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience

Po-Ting Lin, Rachel Wen-Juei Jeng, Yi-Chung Hsieh, Wei Teng, Chen-Fu Hung, Chien-Hao Huang, Kar-Wai Lui, Yi-Cheng Chen, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

Original language	American English
Journal	Journal of Hepatology
Volume	70
Issue number	1
DOIs	https://doi.org/10.1016/S0618-8278(19)31232-0
State	Published - 2019

Access to Document

10.1016/S0618-8278(19)31232-0

Cite this

Lin, P.-T., Jeng, R. W.-J., Hsieh, Y.-C., Teng, W., Hung, C.-F., Huang, C.-H., Lui, K.-W., Chen, Y.-C., Lin, C.-C., Lin, C.-Y., Lin, S.-M., & Sheen, I.-S. (2019). Shifting to sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience. Journal of Hepatology, 70(1). https://doi.org/10.1016/S0618-8278(19)31232-0

@article{59a143a3b64343f0b8c51ee055142008,

title = "Shifting to sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience",

author = "Po-Ting Lin and Jeng, {Rachel Wen-Juei} and Yi-Chung Hsieh and Wei Teng and Chen-Fu Hung and Chien-Hao Huang and Kar-Wai Lui and Yi-Cheng Chen and Chen-Chun Lin and Chun-Yen Lin and Shi-Ming Lin and I-Shyan Sheen",

year = "2019",

doi = "10.1016/S0618-8278(19)31232-0",

language = "American English",

volume = "70",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "1",

}

Lin, P-T, Jeng, RW-J, Hsieh, Y-C, Teng, W, Hung, C-F, Huang, C-H, Lui, K-W, Chen, Y-C, Lin, C-C, Lin, C-Y, Lin, S-M & Sheen, I-S 2019, 'Shifting to sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience', Journal of Hepatology, vol. 70, no. 1. https://doi.org/10.1016/S0618-8278(19)31232-0

TY - JOUR

T1 - Shifting to sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience

AU - Lin, Po-Ting

AU - Jeng, Rachel Wen-Juei

AU - Hsieh, Yi-Chung

AU - Teng, Wei

AU - Hung, Chen-Fu

AU - Huang, Chien-Hao

AU - Lui, Kar-Wai

AU - Chen, Yi-Cheng

AU - Lin, Chen-Chun

AU - Lin, Chun-Yen

AU - Lin, Shi-Ming

AU - Sheen, I-Shyan

PY - 2019

Y1 - 2019

U2 - 10.1016/S0618-8278(19)31232-0

DO - 10.1016/S0618-8278(19)31232-0

M3 - Journal Article

SN - 0168-8278

VL - 70

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 1

ER -